FDA approves daratumumab plus VMP for transplant ineligible myeloma patients


On 7 May 2018 the US FDA approved daratumumab (DARZALEX®) in combination with the VMP regimen (bortezomib (VELCADE®), melphalan, and prednisone) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).

Ribociclib FDA label updated to include pre- and perimenopausal women